Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 11.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has metastatic or locally advanced solid tumor or multiple myeloma~* Tumor specimen has IGF-1R expression~* Participant agrees to use birth control throughout study~Exclusion Criteria:~* Participant must not be recovering from antineoplastic therapy in the last 4 weeks~* Participant has participated in a clinical trial in the last 4 weeks~* Participant has a history of heart problems such as congestive heart failure, angina, heart attack or stroke in the last 3 months~* Participant is taking growth hormone or growth hormone inhibitors~* If female, participant is pregnant or breastfeeding~* Participant is human immunodeficiency virus (HIV) positive~* Participant has a history of hepatitis B or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dalotuzumab 1.25 mg/kg Q1W (10 mg/mL) (Type: EXPERIMENTAL): Participants received dalotuzumab 1.25 mg/kg (10 mg/mL) intravenous (IV) infusion 1 time every 1 week (Q1W).
- Dalotuzumab 2.5 mg/kg Q1W (10 mg/mL) (Type: EXPERIMENTAL): Participants received dalotuzumab 2.5 mg/kg (10 mg/mL) IV infusion Q1W.
- Dalotuzumab 5 mg/kg Q1W (10 mg/mL) (Type: EXPERIMENTAL): Participants received dalotuzumab 5 mg/kg (10 mg/mL) IV infusion Q1W.
- Dalotuzumab 10 mg/kg Q1W (10 mg/mL) (Type: EXPERIMENTAL): Participants received dalotuzumab 10 mg/kg (10 mg/mL) IV infusion Q1W.
- Dalotuzumab 10 mg/kg Q1W (20 mg/mL) (Type: EXPERIMENTAL): Participants received dalotuzumab 10 mg/kg (20 mg/mL) IV infusion Q1W.
- Dalotuzumab 15 mg/kg Q1W (10 mg/mL) (Type: EXPERIMENTAL): Participants received dalotuzumab 15 mg/kg (10 mg/mL) IV infusion Q1W.
- Dalotuzumab 15 mg/kg Q1W (20 mg/mL) (Type: EXPERIMENTAL): Participants received dalotuzumab 15 mg/kg (20 mg/ mL) IV infusion Q1W.
- Dalotuzumab 20 mg/kg Q1W (10 mg/mL) (Type: EXPERIMENTAL): Participants received dalotuzumab 20 mg/kg (10 mg/mL) IV infusion Q1W.
- Dalotuzumab 20 mg/kg Q1W (20 mg/mL) (Type: EXPERIMENTAL): Participants received dalotuzumab 20.0 mg/kg (20 mg/mL) IV infusion Q1W.
- Dalotuzumab 20 mg/kg Q2W (20 mg/mL) (Type: EXPERIMENTAL): Participants received dalotuzumab 20 mg/kg (20 mg/mL) IV infusion 1 time every 2 weeks (Q2W).
- Dalotuzumab 30 mg/kg Q3W (20 mg/mL) (Type: EXPERIMENTAL): Participants received dalotuzumab 30 mg/kg (20 mg/mL) IV infusion1 time every 3 weeks (Q3W).

Based on this trial design, predict the completion outcome and termination type (if applicable).